Clinical Trial

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

Study acronym: FLAGSHP-1
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
* To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors. * To determine the Maximum Tolerated Dose (MTD) and/or recommended dose (RD) of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. * To characterize the pharmacokinetic (PK) profile of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2020-12-15; most recent amendment 2026-03-23.
Status change: Recruiting → Active, Not Recruiting 2023-11-27
Trial Details
NCT Number NCT04670679
Lead Sponsor Erasca, Inc.
Conditions Advanced or Metastatic Solid Tumors
Enrollment 90 participants
Start Date 2020-12-15
Primary Completion 2026-02-01 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-25